Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.
Inozyme Pharma, Inc. (INZY) is a clinical-stage biopharmaceutical company pioneering enzyme replacement therapies for rare mineralization disorders. This page provides investors and healthcare stakeholders with essential updates on INZY's progress in addressing conditions like ENPP1 Deficiency and calciphylaxis through its lead candidate INZ-701.
Access consolidated news about clinical trial developments, regulatory milestones, and scientific advancements. Our repository includes press releases on study results, partnership announcements with research organizations, and analyses of INZY's therapeutic approach targeting the PPi-Adenosine pathway.
Key updates cover safety/efficacy data from ongoing trials, manufacturing collaborations, and presentations at medical conferences. Bookmark this page to efficiently track INZY's progress in developing treatments for diseases with significant unmet needs.
Inozyme Pharma (Nasdaq: INZY) announced the appointment of Sanjay S. Subramanian as CFO and Soojin Kim, Ph.D., as CTOO. Subramanian brings over 20 years of financial expertise, previously raising over $200 million at Ocugen. Kim, with more than 25 years in pharmaceutical R&D, will enhance the company's manufacturing operations for INZ-701, currently in Phase 1/2 trials for ENPP1 Deficiency. Both executives aim to advance Inozyme's mission in treating rare diseases caused by abnormal mineralization.
Inozyme Pharma (Nasdaq: INZY) announced that co-founder and CEO Axel Bolte will engage in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 11:10 AM ET. This event highlights the company’s commitment to advancing therapies for rare genetic conditions caused by abnormal mineralization, particularly focusing on ENPP1 and ABCC6 deficiencies. A replay of the discussion will be available for 30 days post-event on the Inozyme website.
Inozyme Pharma (Nasdaq: INZY) announced the initiation of its first-in-human Phase 1/2 clinical trial for INZ-701, an enzyme replacement therapy targeting ENPP1 Deficiency. The trial's first patient has been dosed, with preliminary biomarker and safety data expected by mid-2022. This trial will evaluate the safety, tolerability, and pharmacokinetic profiles of INZ-701 in nine adult patients across the U.S. and Europe. ENPP1 Deficiency is a life-threatening condition with no approved treatments, making this milestone significant for patient care and potential market impact.
Inozyme Pharma, a clinical-stage biopharmaceutical company focused on rare diseases of abnormal mineralization, announced that co-founder and CEO Axel Bolte will present at two upcoming virtual investor conferences. The 2021 Jefferies London Virtual Healthcare Conference will feature an on-demand presentation starting November 18, 2021, at 3:00 a.m. ET, while the Piper Sandler 33rd Annual Virtual Healthcare Conference will host a fireside chat available on-demand from November 22, 2021, at 10:00 a.m. ET. Presentations will be accessible for 60 days on the company’s website.
Inozyme Pharma, Inc. (Nasdaq: INZY) reported its third-quarter 2021 financial results, highlighting progress in the INZ-701 program for ENPP1 and ABCC6 Deficiencies. The company anticipates starting Phase 1/2 clinical trials in Q4 2021, with preliminary data expected in early 2022. As of September 30, 2021, cash, cash equivalents, and investments totaled $125.3 million, expected to support operations into Q1 2023. R&D expenses decreased to $9.3 million, while G&A expenses rose to $4.9 million. The net loss improved to $14.3 million, or $0.60 per share, compared to $28.1 million, or $1.55 per share, year-over-year.
Inozyme Pharma (Nasdaq: INZY) presented findings from its ENPP1 Deficiency Natural History Study and gene therapy program at the ASBMR 2021 Annual Meeting. The study, involving 74 patients, showed that 46% had skeletal disease, with 58% experiencing cardiac issues. AAV-ENPP1 gene therapy demonstrated potential in preclinical models, preventing soft tissue calcification and restoring bone parameters. Inozyme plans to begin Phase 1/2 trials for its therapy INZ-701 within Q4 2021 to address this life-threatening condition. Currently, no approved treatments exist for ENPP1 Deficiency.
Inozyme Pharma (Nasdaq: INZY) announced that its CEO, Axel Bolte, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29 at 1:20 p.m. ET. The presentation will focus on the company's development of novel therapeutics for rare diseases related to abnormal mineralization, particularly those caused by mutations in the ENPP1 and ABCC6 genes. Investors can access the live webcast from Inozyme's website, with an archived replay available for 60 days after the event.
Inozyme Pharma received Orphan Drug Designation from the European Medicines Agency for INZ-701 aimed at treating ABCC6 Deficiency. The company’s Clinical Trial Application (CTA) in Europe and Investigational New Drug (IND) application in the U.S. for a Phase 1/2 trial have been accepted. The company expects to enroll patients by Q4 2021 and report preliminary data in H1 2022. As of June 30, 2021, Inozyme had $137.5 million in cash and investments, anticipated to support operations into Q4 2022. The net loss for Q2 2021 was $12.5 million, or $0.53 per share.
Inozyme Pharma (Nasdaq: INZY), a biopharmaceutical company focusing on rare diseases, has announced that Axel Bolte, the co-founder and CEO, will participate in a panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11. The panel, titled UltraOrphan – When You’re One in a Million, is scheduled from 2:55 to 3:25 p.m. ET. Inozyme Pharma aims to develop innovative therapies for diseases related to abnormal mineralization, particularly focusing on genetic conditions linked to the ENPP1 and ABCC6 genes.
Inozyme Pharma (Nasdaq: INZY) announced the European Medicines Agency (EMA) granted Orphan Drug Designation to INZ-701 for treating ABCC6 Deficiency, a rare inherited disorder. This designation follows the earlier Orphan Drug Designation for this therapy for ENPP1 Deficiency. ABCC6 Deficiency can cause severe health issues, including vision loss and cardiovascular complications, with no approved treatments available. The Orphan Drug Designation may provide development incentives and a ten-year market exclusivity post-approval, fostering the potential for INZ-701 to be a first-ever therapy for this condition.
